Charles River Q2: revenue $1.00B, GAAP loss $(0.03), non-GAAP EPS $3.02; guidance raised

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Revenue $1.00B, down 2.7% YoY; organic revenue +0.1%, first positive since Q3 2023.
GAAP net loss $(1.5)M ($(0.03)/diluted share) vs net income $52.3M ($1.06) in Q2 2025; loss driven by $63.7M divestiture loss.
Non-GAAP EPS $3.02, down 3.2% from $3.12; non-GAAP operating margin 20.5% vs 22.1% YoY.
Raises 2026 guidance: organic revenue growth now 0.0%-1.0% (prior -1.5% to -0.5%); non-GAAP EPS $11.15-$11.45 (prior $10.80-$11.30).
Repurchased $100M of stock in Q2 at avg $174/share; $700M remaining under $1B authorization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.